Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA

NCT02629523 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Lung Neoplasms
EGFR Gene Mutation

Interventions

DRUG: Afatinib

Sponsor

Chonnam National University Hospital